# A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

> **NCT05265728** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 21 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT05265728
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-26
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-05-27
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Due to sponsor decision, not for efficacy or safety reasons.
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265728, "A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05265728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*